NCT07900633: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
- State
- Not started
- Phase
- Phase 3
- People
- 3,000 planned
- Started
- Dec 2026
- Primary completion
- Nov 2029
- Arms
- Eloralintide
- Results
- None posted
- 28 Oct 2026: Trial registered